Recursion Pharmaceuticals
RXRX
RXRX
144 hedge funds and large institutions have $953M invested in Recursion Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 62 increasing their positions, 30 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
144
Holders Change
-2
Holders Change %
-1.37%
% of All Funds
2.32%
Holding in Top 10
6
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-25%
% of All Funds
0.1%
New
20
Increased
62
Reduced
30
Closed
19
Calls
$266K
Puts
$172K
Net Calls
+$94K
Net Calls Change
-$553K
Top Buyers
| 1 |
KA
Kinnevik AB
Stockholm,
Sweden
|
$59M |
| 2 |
State Street
Boston,
Massachusetts
|
$60.7M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
$191M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
$77.5M |
| 5 |
BlackRock
New York
|
$82.2M |
